The F.D.A. Suspends Use of Glaxo Antibody Drug in the U.S. April 5, 2022 Auto Bot Coronavirus (2019-nCoV), Coronavirus Omicron Variant, Food and Drug Administration, GlaxoSmithKline PLC 0 Manufacturers said lab testing revealed that the authorized dosage of the drug was not sufficiently potent against BA.2.